Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Accounts Payables (2022 - 2025)

BioXcel Therapeutics has reported Accounts Payables over the past 4 years, most recently at $14.7 million for Q4 2025.

  • Quarterly results put Accounts Payables at $14.7 million for Q4 2025, down 8.06% from a year ago — trailing twelve months through Dec 2025 was $14.7 million (down 8.06% YoY), and the annual figure for FY2025 was $14.7 million, down 8.06%.
  • Accounts Payables for Q4 2025 was $14.7 million at BioXcel Therapeutics, down from $16.3 million in the prior quarter.
  • Over the last five years, Accounts Payables for BTAI hit a ceiling of $17.2 million in Q1 2024 and a floor of $5.1 million in Q1 2022.
  • Median Accounts Payables over the past 4 years was $13.5 million (2023), compared with a mean of $12.2 million.
  • Biggest five-year swings in Accounts Payables: soared 122.42% in 2024 and later fell 10.28% in 2025.
  • BioXcel Therapeutics' Accounts Payables stood at $10.2 million in 2022, then surged by 33.5% to $13.7 million in 2023, then grew by 17.11% to $16.0 million in 2024, then decreased by 8.06% to $14.7 million in 2025.
  • The last three reported values for Accounts Payables were $14.7 million (Q4 2025), $16.3 million (Q3 2025), and $16.7 million (Q2 2025) per Business Quant data.